Cgas Sting Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The cGAS-STING pathway is a critical innate immune signaling cascade that detects cytosolic DNA and triggers type I interferon responses. Emerging research reveals this pathway's central role in chronic neuroinflammation across Alzheimer's disease, Parkinson's disease, ALS, and aging.
The cGAS-STING pathway represents a fundamental mechanism by which the innate immune system detects abnormal DNA accumulation in cells. In neurodegeneration, chronic activation of this pathway contributes to sustained neuroinflammation, microglial priming, and progressive neuronal dysfunction.
flowchart TD
A[Cytosolic DNA<br/>mitochondrial DNA<br/>genomic DNA] --> B[cGAS Binding] -->
B --> C[cGAS Oligomerization<br/>cGAMP Synthesis] -->
C --> D[STING Activation] -->
D --> E[TBK1 Phosphorylation] -->
E --> F{IRF3 vs NF-κB}
F --> G[IRF3 Dimerization] -->
F --> H[NF-κB Activation] -->
G --> I[Type I IFN<br/>Interferon-β<br/>Interferon-α] -->
H --> J[Proinflammatory<br/>Cytokines<br/>IL-6, TNF-α, IL-1β] -->
I --> K[IFNAR Signaling<br/>JAK-STAT] -->
K --> L[ISG Expression<br/>Antiviral Response] -->
J --> M[Microglial<br/>Activation] -->
M --> N[Chronic<br/>Neuroinflammation] -->
L --> N
N --> O[Neuronal<br/>Dysfunction] -->
O --> P[Progressive<br/>Neurodegeneration]
| Molecule |
Symbol |
Function |
Disease Relevance |
| cGAS |
CGAS |
Cytosolic DNA sensor, generates cGAMP |
AD, PD, ALS, aging |
| cGAMP |
cGAMP |
Second messenger, activates STING |
Elevated in AD brain |
| STING |
TMEM173 |
ER-resident adaptor protein |
Central to pathway |
| TBK1 |
TBK1 |
Kinase, phosphorylates IRF3 |
ALS/FTD mutations |
| IRF3 |
IRF3 |
Transcription factor, IFN induction |
Downstream effector |
| NF-κB |
NF-κB |
Proinflammatory transcription factor |
Chronic inflammation |
| IFN-β |
IFNB1 |
Type I interferon |
Elevated in AD/PD CSF |
| IFNAR |
IFNAR |
Type I interferon receptor |
Microglial activation |
cGAS (encoded by the CGAS gene) is a nucleotidyltransferase that binds to double-stranded DNA in the cytosol. When DNA binds, cGAS undergoes a conformational change and oligomerizes into filaments, enabling catalytic activity.
Key activation triggers in neurodegeneration:
- Mitochondrial DNA release: Mitochondrial dysfunction leads to mtDNA leakage into cytosol
- Nuclear DNA damage: Accumulated DNA damage from oxidative stress
- Retrotransposon reactivation: Aging-associated LINE-1 element activation
- Microbial DNA: Potential contribution from chronic infections
¶ cGAMP Production and STING Activation
Once activated, cGAS synthesizes cyclic GMP-AMP (cGAMP) from ATP and GTP. cGAMP then binds to STING (Stimulator of Interferon Genes), causing STING to undergo conformational change and translocate from the ER to the Golgi apparatus.
flowchart LR
subgraph STING Signaling
STING[STING<br/>ER → Golgi] --> TBK1[TBK1<br/>Recruitment] -->
TBK1 --> IRF3[IRF3<br/>Phosphorylation] -->
TBK1 --> IKK[IKK Complex] -->
IRF3 --> IRF3d[IRF3<br/>Dimerization] -->
IKK --> NFKB[NF-κB<br/>Activation] -->
IRF3d --> IFN[IFN-β<br/>Transcription] -->
NFKB --> Cytokines[Proinflammatory<br/>Cytokines]
end
STING activates two primary downstream pathways:
- TBK1-IRF3 pathway: Leads to type I interferon production
- NF-κB pathway: Leads to proinflammatory cytokine production
In AD, the cGAS-STING pathway is chronically activated by multiple mechanisms:
Aβ-induced activation:
- Aβ oligomers cause mitochondrial dysfunction and mtDNA release
- Mitochondrial Aβ accumulation damages mitochondrial membranes
- Damaged mitochondria release mtDNA into cytosol
- cGAS detects mtDNA and triggers STING activation
Evidence in AD:
- Elevated cGAMP levels in AD brain tissue
- Increased STING expression in AD microglia
- Type I interferon signature in AD brain
- cGAS colocalizes with amyloid plaques
Therapeutic implications:
- STING inhibitors (H-151, C-176) reduce neuroinflammation in mouse models
- Genetic deletion of cGAS or STING improves memory in AD mice
- Anti-Aβ therapies may indirectly reduce cGAS-STING activation
In PD, cGAS-STING activation contributes to neuroinflammation:
α-Synuclein-triggered activation:
- α-Synuclein aggregates may cause mitochondrial damage
- Mitochondrial dysfunction leads to mtDNA release
- Microglial cGAS-STING responds to neuronal mtDNA release
Dopaminergic neuron vulnerability:
- High metabolic demand increases mitochondrial stress
- Dopamine oxidation products may damage mitochondria
- SNpc neurons particularly susceptible to cGAS-STING-induced inflammation
Evidence in PD:
- Elevated IFN-β in PD CSF
- STING activation in PD postmortem brain
- LRRK2 mutations may affect STING trafficking
In ALS, cGAS-STING is activated by multiple mechanisms:
TDP-43 pathology:
- TDP-43 mislocalization affects nuclear integrity
- Nuclear envelope damage may allow DNA leakage
- TDP-43 aggregates may directly bind cGAS
C9orf72 repeat expansions:
- Repeat RNA forms DNA:RNA hybrids (R-loops)
- R-loops cause genomic instability
- DNA damage activates cGAS-STING
TBK1 mutations:
- TBK1 loss-of-function mutations common in ALS/FTD
- Impaired TBK1 signaling alters IFN responses
- Creates complex immunomodulatory effects
¶ Aging and Sporadic Neurodegeneration
The cGAS-STING pathway provides a mechanistic link between aging and neurodegeneration:
- Mitochondrial dysfunction: Cumulative mtDNA damage with age
- Senescence-associated DNA damage: Accumulated DNA lesions
- Immune senescence: Microglial priming increases responsiveness
- Chronic low-level inflammation: "Inflammaging" phenotype
| Drug/Compound |
Target |
Stage |
Notes |
| H-151 |
STING |
Preclinical |
Covalent inhibitor, blocks STING palmitoylation |
| C-176 |
STING |
Preclinical |
Blocks STING function |
| A-1899 |
STING |
Preclinical |
Cyclic dinucleotide antagonist |
| AS-703 |
cGAS |
Preclinical |
Inhibits cGAS catalytic activity |
| RU.521 |
cGAS |
Preclinical |
Selective cGAS inhibitor |
| Strategy |
Mechanism |
Status |
| Mitochondrial protectants |
Reduce mtDNA release |
CoQ10, MitoQ in trials |
| Antioxidants |
Reduce oxidative DNA damage |
N-acetylcysteine |
| DNA repair enhancers |
Reduce genomic DNA damage |
PARP inhibitors |
| Anti-aggregation therapies |
Reduce protein aggregate toxicity |
Various in trials |
- Metformin: May reduce cGAS-STING through AMPK
- Aspirin: NF-κB inhibition downstream of STING
- Minocycline: Broad anti-inflammatory effects
- Hydroxychloroquine: Lysosomal inhibition affects STING trafficking
| Biomarker |
Source |
Relevance |
| cGAMP |
CSF, blood |
Direct pathway activation |
| IFN-β |
CSF, blood |
Type I interferon response |
| CXCL10/IP-10 |
CSF, blood |
IFN-stimulated chemokine |
| STING expression |
Blood cells |
Pathway activation state |
| p-TBK1 |
Blood cells |
Downstream signaling |
The cGAS-STING pathway intersects with multiple neurodegenerative mechanisms:
- Neuroinflammation: Amplifies microglial activation and cytokine production
- Mitochondrial dysfunction: Bidirectional - mtDNA release activates pathway
- DNA damage response: DNA damage activates cGAS
- Aging: Cumulative DNA damage increases activation
- Neuroimmune checkpoint: TREM2 signaling may modulate cGAS-STING
- Autophagy: Mitophagy defects increase cytosolic mtDNA
- What is the relative contribution of neuronal vs. glial cGAS-STING activation?
- Can peripheral immune modulation affect CNS cGAS-STING activity?
- What determines the balance between protective IFN responses vs. pathological chronic inflammation?
- Does genetic variation in cGAS/STING modify neurodegeneration risk?
- Can timing of intervention determine therapeutic efficacy?
The study of Cgas Sting Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- A dual role of cGAS in Alzheimer's disease. Nat Neurosci. 2024.
- STING mediates neurodegeneration in Parkinson's disease models. Neuron. 2023.
- cGAS-STING activation in amyotrophic lateral sclerosis. Acta Neuropathol. 2023.
- Mitochondrial DNA release triggers cGAS-STING in neurodegeneration. Cell. 2022.
- STING inhibition reduces neuroinflammation in AD mouse models. Brain. 2022.
- Cytosolic DNA sensing in innate immunity of the brain. Nat Rev Immunol. 2021.
- cGAS-STING and aging: linking DNA damage to neurodegeneration. Aging Cell. 2021.
- TBK1 mutations in ALS/FTD: effects on innate immune signaling. Nat Neurosci. 2020.
- Microglial cGAS-STING in tau pathology. J Exp Med. 2020.
- Type I interferon signature in neurodegenerative diseases. Brain. 2019.
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 31%